Vaxil Reports Preliminary Data From Checkpoint Inhibitors in Combination With Immucin(TM)
29 nov. 2016 09h00 HE
|
Vaxil Bio Ltd.
TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - November 29, 2016) - VAXIL BIO LTD. (TSX VENTURE: VXL) is pleased to report preliminary pre-clinical results demonstrating anti-cancer activity of...
Vaxil Announces Strategic Collaboration With Hadassah
20 oct. 2016 09h00 HE
|
Vaxil Bio Ltd.
TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - October 20, 2016) - VAXIL BIO LTD. (TSX VENTURE: VXL), is pleased to announce a collaboration with Hadassah Medical Center, one of Israel's leading...
Vaxil Announces Key US Patent and Trademark Office Notice of Allowance for Its Immunotherapy
04 août 2016 09h00 HE
|
Vaxil Bio Ltd.
TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - August 04, 2016) - VAXIL BIO (TSX VENTURE: VXL),a biotechnology company specializing in immunotherapy, announces today that it has received a Notice of...
Vaxil Receives Positive Response From European Patent Office for the Allowance of the Immunotherapy Orphan Drug Designated ImMucin(TM)
16 juin 2016 09h30 HE
|
Vaxil Bio Ltd.
TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - June 16, 2016) - VAXIL BIO LTD. (TSX VENTURE: VXL), an Israeli biotech specializing in immuno-oncology, reports that it has successfully received a...
Vaxil Receives Canadian Notice of Patent Allowance for Its Lead Immunotherapy Platform, Including Its ImMucin(TM) Cancer Vaccine
31 mars 2016 09h15 HE
|
Vaxil Bio Ltd.
TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - March 31, 2016) -
VAXIL BIO LTD.
(TSX VENTURE: VXL), an Israeli biotechnology company specializing in cancer immunotherapy, is very...
Vaxil Becomes First Israeli Biotech to List on TSX-Venture
10 mars 2016 09h30 HE
|
Vaxil Bio Ltd.
TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - March 10, 2016) -
Vaxil Bio Ltd. ("Vaxil" or the "Company") (TSX VENTURE: VXL) wishes to announce the closing of its go-public via reverse...